Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...

Sixth batch under investment-attraction initiative to also feature Boehringer Ingelheim, Hengrui and HAYA, with DiDi and ...

In the latest close session, Amgen (AMGN) was up +1.69% at $355.30. This move outpaced the S&P 500's daily gain of 1.2%. Elsewhere, the Dow gained 1.79%, while the tech-heavy Nasdaq added 1.52%. Prior ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

If you are wondering whether Amgen’s recent share price puts it on sale or at a premium, and what that really means for your ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, UBS lifted its price ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 Overlooked Growth Stocks to Buy Now. Zai Lab Limited (NASDAQ:ZLAB) is one of ...

By Puyaan Singh March 31 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has identified cases of liver injury in patients taking Amgen's drug for a group of rare autoimmune ...